📉 The Financial Deep Dive
Suraksha Diagnostic Limited has charted a course of aggressive growth, unveiling strong financial performance for the third quarter and nine months ended December 31, 2025 (Q3 and 9M FY26).
The Numbers: Q3 FY26 Performance
For the quarter, Total Income surged by a notable 30.3% year-on-year (YoY) to ₹783 million, up from ₹601 million in Q3 FY25. EBITDA followed suit, increasing by 26.1% YoY to ₹237.8 million. However, this expansion came at the cost of margin compression, with the EBITDA margin declining to 30.6% from 31.7% in the prior year's quarter. Profit After Tax (PAT) saw a 21.0% YoY increase to ₹72.4 million, while the PAT margin narrowed to 9.3% from 10.1% YoY.
The Numbers: 9M FY26 Performance
The nine-month period ending December 31, 2025, showed sustained revenue momentum, with Total Income growing 21.8% YoY to ₹2,313.8 million from ₹1,900.3 million in 9M FY25. EBITDA for 9M FY26 reached ₹734 million, an increase of 12.8% YoY. Here too, margins compressed, with the EBITDA margin at 31.7%, down from 34.8% in 9M FY25. PAT for the period grew 6.0% YoY to ₹252.4 million, with the PAT margin at 11.0% compared to 12.7% YoY.
Full Year FY25 Highlights
For the full fiscal year 2025, Suraksha Diagnostic reported Total Revenue of ₹2,559.4 million (a 15.2% YoY growth), EBITDA of ₹850.9 million (a 15.6% YoY growth) with a stable margin of 33.8%, and PAT of ₹309.8 million (a significant 34.0% YoY growth).
The Strategy: Investing for Scale
Management commentary attributes the revenue growth to an aggressive expansion plan, evidenced by 12 operational centers and 6 under development. The slight margin compression in Q3 and 9M FY26 is a direct result of planned pre-operative expenses for these new centers. Crucially, the core business—centers older than two years—maintains a robust 37% EBITDA margin, validating the company's 'hub and spoke' model. This 'Investing for Scale' strategy prioritizes market share and long-term dominance over immediate profitability.
Strategic Developments
The company has made strategic moves to enhance its offerings. In April 2025, Suraksha Diagnostic acquired a 63% stake in Fetomat Wellness Private Limited, a network of fertility and pregnancy care clinics (FY24 turnover ₹4.11 crore, EBITDA ₹0.56 crore). Furthermore, the launch of Suraksha Genomics in July 2025 marks a significant entry into advanced genetic and molecular testing, aiming to capitalize on high-impact domains like whole genome sequencing and establish a first-mover advantage in Eastern India.
Financial Deep Dive: Balance Sheet
Indicative of ongoing expansion, the balance sheet shows a consistent increase in Property, Plant, and Equipment (₹1,471.4 million in FY25 vs ₹1,350.5 million in FY24) and a substantial rise in Capital Work-in-Progress (₹100.99 million in FY25 vs ₹13.13 million in FY24). The company's debt position has strengthened, moving from a net debt of ₹134.5 million in FY23 to net cash of ₹35.8 million in FY25, a marked improvement from net cash of ₹61.2 million in FY24.
Industry Context & Outlook
The Indian diagnostic market is projected for high growth (10-12% CAGR FY24-FY28), with organized players gaining traction. Eastern India is identified as an underserved region with premium pricing potential, expected to grow at 10.5-12.5% CAGR. Suraksha Diagnostic is strategically positioned to leverage its established presence in this lucrative market and capitalize on its new genomics vertical. The company plans to open 6 more centers in Q4 FY26, further accelerating its expansion.
Risks & Outlook
The primary risk remains the execution of its ambitious expansion plans and the successful integration of new ventures like Fetomat and Suraksha Genomics. Continued investment in pre-operative expenses could keep margins under pressure in the short term. However, the company's long-term outlook appears positive, driven by market growth, strategic diversification, and a clear focus on scaling operations.